照護現場傳染病檢查市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計照護現場傳染病檢查市場規模將從 2025 年的 184.2 億美元成長到 2034 年的 285.1 億美元，2026 年至 2034 年的複合年成長率為 4.97%。

隨著感染疾病的增加，對快速、準確的診斷解決方案的需求日益成長，全球照護現場（POC​​）傳染病檢查市場預計將顯著成長。新冠肺炎疫情凸顯了及時檢測在控制疫情傳播和有效管理公共衛生的重要性。即時檢測的優點在於可在數分鐘內提供結果，使醫護人員能夠迅速做出明智的決策並啟動適當的治療。隨著人們越來越重視感染疾病的早期發現和預防，即時檢測解決方案的普及預計將加速，從而推動這一重要市場的創新和投資。

此外，技術進步可望徹底改變即時傳染病檢查領域。分子診斷、微流體和生物感測器的整合正在提高檢測的靈敏度和特異性，從而能夠檢測包括細菌、病毒和寄生蟲在內的多種病原體。同時，可在從診所到偏遠地區等各種環境下運行的便捷型設備的開發，正在擴大檢測的覆蓋範圍。隨著醫療系統日益重視分散式檢查方法，對能夠即時提供準確結果的創新即時檢測解決方案的需求將持續成長。

此外，對個人化醫療的日益重視以及對全球健康舉措的日益關注預計將塑造即時傳染病檢查市場的未來。隨著醫療服務提供者尋求根據患者的個別需求量身定做治療方案，對能夠指南臨床決策的快速診斷工具的需求變得至關重要。即時檢測順應了這一趨勢，使醫務人員能夠快速評估患者病情並相應地調整治療方案。此外，旨在對抗感染疾病（尤其是在資源匱乏地區）的全球健康舉措正在推動對可在各種環境下部署的即時檢測技術的投資。診斷設備製造商、醫療機構和公共衛生機構之間的合作對於推動這些解決方案的實施至關重要，並確保即時傳染病檢查市場保持敏捷性，能夠應對不斷湧現的健康挑戰。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 繪製滲透率和成長前景圖
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 市場問題
• 波特五力分析
• PESTLE分析

4. 全球照護現場傳染病檢查市場（依技術分類）

• 市場分析、洞察與預測
• 側向流動免疫檢測
• 凝集試驗
• 流通式檢測/免疫濃縮試驗
• 分子診斷
• 其他

5. 全球照護現場傳染病檢查市場（依疾病分類）

• 市場分析、洞察與預測
• HIV POC
• 困難梭狀芽孢桿菌傳染病
• HBV POC
• 肺炎或鏈球菌感染疾病
• 呼吸道融合細胞病毒（RSV）即時偵測
• HPV POC
• 流感/即時檢測
• HCV POC
• MRSA POC
• 結核病和抗藥性結核病的即時檢測
• HSV POC
• 新型冠狀病毒感染疾病（COVID-19）
• 其他

6. 全球照護現場傳染病檢查市場（依最終用途分類）

• 市場分析、洞察與預測
• 診所
• 醫院
• 家
• 生活協助設施
• 檢查機構

7. 全球照護現場傳染病檢查市場（按地區分類）

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商格局（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Abbott
  • Thermo Fisher Scientific Inc
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers
  • Becton
  • Dickinson & Company
  • Chembio Diagnostics Inc
  • Trinity Biotech
  • Cardinal Health
  • Quest Diagnostics Incorporated
  • Bio-Rad Laboratories Inc
  • BioMAfA（C）Rieux SA
  • Sight Diagnostics Ltd
  • Gene POC
  • Trivitron Healthcare
  • OJ-Bio Ltd
  • Ortho-Clinical Diagnostics

The Point of Care Infectious Disease Testing Market size is expected to reach USD 28.51 Billion in 2034 from USD 18.42 Billion (2025) growing at a CAGR of 4.97% during 2026-2034.

The global point of care (POC) infectious disease testing market is poised for significant growth, driven by the increasing demand for rapid and accurate diagnostic solutions in the face of rising infectious diseases. The COVID-19 pandemic has underscored the critical need for timely testing to control outbreaks and manage public health effectively. POC testing offers the advantage of delivering results within minutes, enabling healthcare providers to make informed decisions quickly and initiate appropriate treatment. As the focus on early detection and prevention of infectious diseases intensifies, the adoption of POC testing solutions is expected to accelerate, fostering innovation and investment in this vital market.

Moreover, advancements in technology are set to transform the POC infectious disease testing landscape. The integration of molecular diagnostics, microfluidics, and biosensors is enhancing the sensitivity and specificity of tests, allowing for the detection of a wide range of pathogens, including bacteria, viruses, and parasites. Additionally, the development of user-friendly devices that can be operated in various settings, from clinics to remote locations, is expanding access to testing. As healthcare systems increasingly prioritize decentralized testing approaches, the demand for innovative POC solutions that can deliver accurate results in real-time will continue to rise.

In addition, the growing emphasis on personalized medicine and the increasing focus on global health initiatives are expected to shape the future of the POC infectious disease testing market . As healthcare providers seek to tailor treatments to individual patient needs, the demand for rapid diagnostic tools that can inform clinical decisions is becoming paramount. POC testing aligns with this trend by enabling healthcare professionals to quickly assess a patient's condition and adjust treatment plans accordingly. Furthermore, global health initiatives aimed at combating infectious diseases, particularly in low-resource settings, are driving investments in POC testing technologies that can be deployed in diverse environments. Collaborative efforts between diagnostic manufacturers, healthcare organizations, and public health agencies will be essential in advancing these solutions, ensuring that the POC infectious disease testing market remains agile and responsive to emerging health challenges.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• Lateral Flow Immunoassay
• Agglutination Test
• Flow-Through Test/Immunoconcentration Assay
• Molecular Diagnostics
• Others

By Disease

• HIV POC
• Clostridium Difficile Poc
• HBV POC
• Pneumonia Or Streptococcus Associated Infections
• Respiratory Syncytial Virus (Rsv) POC
• HPV POC
• Influenza/Flu POC
• HCV POC
• MRSA POC
• TB & Drug-Resistant Tb Poc
• HSV POC
• Covid-19
• Others

By End Use

• Clinics
• Hospitals
• Home
• Assisted Living Healthcare Facilities
• Laboratory

COMPANIES PROFILED

• Abbott, Thermo Fisher Scientific Inc, F HoffmannLa Roche Ltd, Siemens Healthineers, Becton, Dickinson Company, Chembio Diagnostics Inc, Trinity Biotech, Cardinal Health, Quest Diagnostics Incorporated, BioRad Laboratories Inc, bioMrieux SA, Sight Diagnostics Ltd, Gene POC, Trivitron Healthcare, OJBio Ltd, OrthoClinical Diagnostics

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Lateral Flow Immunoassay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Agglutination Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Flow-Through Test/Immunoconcentration Assay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Molecular Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING MARKET: BY DISEASE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease
• 5.2. HIV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Clostridium Difficile Poc Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. HBV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Pneumonia Or Streptococcus Associated Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Respiratory Syncytial Virus (Rsv) POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. HPV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Influenza/Flu POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. HCV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. MRSA POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. TB & Drug-Resistant Tb Poc Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.12. HSV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.13. Covid-19 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.14. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Home Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Assisted Living Healthcare Facilities Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Laboratory Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Technology
  • 7.2.2 By Disease
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Technology
  • 7.3.2 By Disease
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Technology
  • 7.4.2 By Disease
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Technology
  • 7.5.2 By Disease
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Technology
  • 7.6.2 By Disease
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Abbott
  • 9.2.2 Thermo Fisher Scientific Inc
  • 9.2.3 F. Hoffmann-La Roche Ltd
  • 9.2.4 Siemens Healthineers
  • 9.2.5 Becton
  • 9.2.6 Dickinson & Company
  • 9.2.7 Chembio Diagnostics Inc
  • 9.2.8 Trinity Biotech
  • 9.2.9 Cardinal Health
  • 9.2.10 Quest Diagnostics Incorporated
  • 9.2.11 Bio-Rad Laboratories Inc
  • 9.2.12 BioMAfA(C)Rieux SA
  • 9.2.13 Sight Diagnostics Ltd
  • 9.2.14 Gene POC
  • 9.2.15 Trivitron Healthcare
  • 9.2.16 OJ-Bio Ltd
  • 9.2.17 Ortho-Clinical Diagnostics